Literature DB >> 9628461

Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis.

F Sellebjerg1, J Jensen, L P Ryder.   

Abstract

The costimulatory CD80 and CD86 molecules were measured by flow cytometry on cerebrospinal fluid (CSF) and blood lymphocytes from patients with possible first attacks of multiple sclerosis (MS, n = 25), clinically definite MS (n = 16), and noninflammatory neurological disease control subjects (n = 30). In patients with demyelinating diseases more CSF B cells expressed CD80 than in control subjects whereas the expression of CD86 by T cells in CSF was low in patients with demyelinating disease and highly variable in the control subjects. In patients with possible first attacks of MS the expression pattern of CD80 and CD86 differed significantly between patients with or without intrathecal synthesis of IgG. Increased expression of the CD80 molecule on CSF B cells may be of importance in the pathogenesis of MS. In contrast, CSF T cell expression of CD86 may be associated with protection from MS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628461     DOI: 10.1016/s0165-5728(97)00261-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

Review 3.  The potential role of B cell-targeted therapies in multiple sclerosis.

Authors:  Aaron Boster; Daniel P Ankeny; Michael K Racke
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

Review 4.  A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Avijit Ray; Monica K Mann; Sreemanti Basu; Bonnie N Dittel
Journal:  J Neuroimmunol       Date:  2010-12-10       Impact factor: 3.478

5.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.

Authors:  T L Sørensen; M Tani; J Jensen; V Pierce; C Lucchinetti; V A Folcik; S Qin; J Rottman; F Sellebjerg; R M Strieter; J L Frederiksen; R M Ransohoff
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

6.  B cells as a target of immune modulation.

Authors:  Kathleen Hawker
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

7.  Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Dan Hesse; Martin Krakauer; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  J Neuroinflammation       Date:  2012-09-14       Impact factor: 8.322

8.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Authors:  Soraya Maria Menezes; Daniele Decanine; David Brassat; Ricardo Khouri; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Anne-Mieke Vandamme; Bernardo Galvão-Castro; Roland Liblau; Johan Van Weyenbergh
Journal:  J Neuroinflammation       Date:  2014-01-29       Impact factor: 8.322

10.  Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.

Authors:  Jason Stein; Quangang Xu; Kayla C Jackson; Elena Romm; Simone C Wuest; Peter Kosa; Tianxia Wu; Bibiana Bielekova
Journal:  Front Neurol       Date:  2018-07-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.